Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Loomis Sayles Global Growth Fund. This analysis is provided for institutional research purposes only and is not investment advice.
"Loomis Sayles Global Growth Fund returned 7.59% in Q3 2025, narrowly trailing its benchmark, while selectively adding to healthcare holdings on price weakness. The portfolio remains anchored in high-quality compounders trading at an estimated 43% discount to intrinsic value."
During the quarter ending September 30, 2025, the Loomis Sayles Global Growth Fund posted a return of 7.59% (Class Y), slightly underperforming its MSCI ACWI benchmark by 0.03%. Top performance contributors were Tesla, Alphabet, and Oracle, while MercadoLibre, Netflix, and Adyen were the largest detractors. In terms of activity, the fund did not make any new purchases but selectively added to existing holdings in Novo Nordisk and Vertex, which was funded by trimming Alibaba. The fund continues to operate with low turnover (estimated 9.0% annualized since inception) and a concentrated high-conviction exposure to mega/large-cap structural winners in sectors like communication services, information technology, and consumer discretionary, maintaining a collective 43% discount to its estimated intrinsic portfolio value.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High-conviction positioning: Loomis Sayles Global Growth Fund returned 7.59% in Q3 2025, narrowly trailing its benchmark, while selectively adding to healthcare holdings on price weakness. The portfolio remain...
Growth Outlook
Market outlook remains above average conviction: Loomis Sayles Global Growth Fund returned 7.59% in Q3 2025, narrowly trailing its benchmark, while selectively adding to healthcare holdings on price weakness. The portfolio remain...
Risk Appetite
Risk appetite posture is above average conviction: Loomis Sayles Global Growth Fund returned 7.59% in Q3 2025, narrowly trailing its benchmark, while selectively adding to healthcare holdings on price weakness. The portfolio remain...
Capital Deployment
Manager actively deployed capital into high-conviction opportunities. Loomis Sayles Global Growth Fund returned 7.59% in Q3 2025, narrowly trailing its benchmark, while selectively adding to healthcare holdings on price weakness. The portfolio remain...
Forward Guidance
Forward guidance signal: Loomis Sayles Global Growth Fund returned 7.59% in Q3 2025, narrowly trailing its benchmark, while selectively adding to healthcare holdings on price weakness. The portfolio remain...
Language Signal
Tone analysis indicates high conviction language: Loomis Sayles Global Growth Fund returned 7.59% in Q3 2025, narrowly trailing its benchmark, while selectively adding to healthcare holdings on price weakness. The portfolio remain...
Perceived Risk
Perceived risk level is evaluated as moderate conviction. Loomis Sayles Global Growth Fund returned 7.59% in Q3 2025, narrowly trailing its benchmark, while selectively adding to healthcare holdings on price weakness. The portfolio remain...
Opportunity Density
Opportunity density index indicates above average conviction actionable entry points. Loomis Sayles Global Growth Fund returned 7.59% in Q3 2025, narrowly trailing its benchmark, while selectively adding to healthcare holdings on price weakness. The portfolio remain...
Time Horizon
Investment time horizon reflects a high conviction orientation. Loomis Sayles Global Growth Fund returned 7.59% in Q3 2025, narrowly trailing its benchmark, while selectively adding to healthcare holdings on price weakness. The portfolio remain...
